Last Updated: October 31st, 2025
We applied early economic modeling and scenario analysis to shape Health Technology Assessment (HTA) submission strategies, optimize price potential, and adapt continuously as new clinical evidence emerged.
What Is Early Modeling for Price Potential & HTA Strategy?
Our early modeling utilizes a preliminary, early cost-effectiveness Markov model to assess a product’s potential pricing outlook prior to launch. This approach forecasts how HTA bodies might assess cost per QALY, tests structural assumptions, and shapes evidence generation strategies to support access.
How Our Technology Delivers Results
We are technically astute, with experts who bring deep healthcare strategy and clinical knowledge to every project. Our work included:
Early Model
Built an early cost-effectiveness Markov model using Fiecon, a Herspiegel company’s Model Builder, to estimate cost per QALY compared to long-term prevention treatments from a health system perspective over a lifetime.
Scenario Analysis
Enabled users to explore cost-effectiveness drivers by adjusting settings such as treatment sequence, usage, discontinuation, population subgroups, and cost/clinical inputs.
HTA Strategy
Conducted a critical appraisal of comparator models to test assumptions based on precedents in HTA submissions.
How Our Practical Agility Keeps Teams Ahead
We operate with an agile structure that enables seamless teamwork and swift resource deployment, ensuring efficient project completion. Our approach included:
- Evidence generation strategy: Performed one-way sensitivity analyses and value of information analyses, providing targeted recommendations for evidence generation based on limited available data.
- Continual model updates: Iteratively refined the model with emerging clinical and pivotal trial data across key comparators to ensure relevance and accuracy.
Customer Testimonies
Why Early Modeling Matters for Pricing & Access
Global price targeting sets realistic pricing expectations before HTA review, identifies critical evidence needs early to guide smarter data collection, and provides flexibility to refine assumptions as data matures. Together, these actions strengthen reimbursement strategies and ensure alignment with payer requirements.
A Step Forward in Strategic Pricing & Access
By combining technical expertise with practical agility, early modeling enables companies to evaluate pricing potential and develop stronger HTA strategies. This proactive approach reduces uncertainty, informs access planning, and increases the likelihood of market success.
Is your HTA strategy built on early pricing insights?
Meet our Modeling Team
Holly Guy
Executive Director
She brings extensive HEOR experience across the product lifecycle, with 30+ successful HTA submissions to NICE, SMC, AWMSG, and other European agencies. She has represented pharma companies at appraisal committee meetings and led the team behind the first new advanced ovarian cancer treatment approved in nearly 20 years.
FAQs on Early Modeling for Price Potential & HTA
- When should early modeling begin?
During late-clinical or pre-launch phases, key inputs are available before full evidence is complete. - What structural settings are typically tested?
Treatment sequence, usage, discontinuation, patient subgroups, and cost/clinical inputs. - How do sensitivity and value of information analyses help?
They highlight which inputs most affect outcomes, guiding evidence generation priorities. - What does the HTA strategy involve in this context?
Critical appraisals, assumption testing, and comparator benchmarking to shape HTA body perceptions. - What are the usual deliverables?
Early cost-effectiveness model, scenario analyses, sensitivity analyses, and updated evidence generation plan.